Journal: Translational Oncology

Article Title: Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET 1

doi:

Figure Lengend Snippet: Everolimus decreases FDG uptake by human H596 lung tumor xenografts. Human tumors were created by s.c. implantation of viable H596 tumor tissue in Harlan athymic mice. (A) For efficacy, mice were treated with vehicle or with everolimus (10 mg/kg p.o.) for 21 days. Results show mean ± SEM. (B and C) A separate cohort of tumor-bearing mice was studied by FDG-PET as described in the Materials and Methods section, immediately before and 2 days after treatment with everolimus. Results show the individual SUVs for tumors (n = 10 per treatment group) and the mean ± SEM fractional effect of treatment, where *P < .05, **P <.01. (D) Histology and IHC of ablated tumors on day 2 after completion of the second PET scan.

Article Snippet: Female Brown-Norway rats and C57BL/6 mice were obtained from Charles River (France) and female Harlan Hsd:Npa nu/nu (nude) athymic mice were obtained from the Novartis breeding stock (Basel, Switzerland).

Techniques:

Journal: Translational Oncology

Article Title: Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET 1

doi:

Figure Lengend Snippet: Everolimus inhibits growth of insensitive human tumors but does not affect FDG uptake. Human HCT116 (colon) and KB31 (cervical) were created by s.c. injection of cells in Harlan athymic mice. In all cases, mice were treated daily p.o. with vehicle or everolimus (10 mg/kg). (A and B) Efficacy in HCT116 tumors for 1 week (A) or 2 weeks (B) showing the mean ± SEM with the associated T/CTVol at the end point. (C and D) FDG-PET in HCT116 tumors in the respective experiment showing the mean fractional change for each treatment compared with day 0 (C) or the individual tumor SUV at two different time points (D). (E and F) Efficacy in KB31 tumors with the fractional change in FDG-PET compared with day 0 for each treatment, where *P < .05, ***P < .001.

Article Snippet: Female Brown-Norway rats and C57BL/6 mice were obtained from Charles River (France) and female Harlan Hsd:Npa nu/nu (nude) athymic mice were obtained from the Novartis breeding stock (Basel, Switzerland).

Techniques: Injection

Journal: Translational Oncology

Article Title: Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET 1

doi:

Figure Lengend Snippet: Everolimus decreases FLT uptake by human H596 lung tumor xenografts. Human tumors were created by s.c. implantation of viable H596 tumor tissue in Harlan athymic mice. Tumors were studied by FLT-PET as described in the Materials and Methods section, immediately before and 2 days after treatment with everolimus (10 mg/kg p.o.). (A) Representative experiment showing horizontal whole-body images of mice with tumors (blue arrow) before and after treatment with everolimus; red arrow indicates the bladder. (B) Individual SUVs for tumors (n = 6 per treatment group), and the mean ± SEM fractional effect of treatment, where **P < .01. (C) Histology and IHC of ablated tumors on day 2 after completion of the second PET scan.

Article Snippet: Female Brown-Norway rats and C57BL/6 mice were obtained from Charles River (France) and female Harlan Hsd:Npa nu/nu (nude) athymic mice were obtained from the Novartis breeding stock (Basel, Switzerland).

Techniques:

Journal: Translational Oncology

Article Title: Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET 1

doi:

Figure Lengend Snippet: Everolimus does not affect FLT uptake by human HCT116 colon tumor xenografts. Human HCT116 tumors were created by s.c. injection of cells in Harlan athymic mice. (A and B) Tumors were studied by FLT-PET as described in the Materials and Methods section, immediately before (day 0) and on days 3 and 10 after treatment with vehicle or everolimus (10 mg/kg p.o.). Results show (n = 6 per treatment group) the individual SUVs for tumors (A) and the mean ± SEM fractional effect of treatment (B). (C) Histology and IHC of ablated tumors on day 10 after completion of the second PET scan.

Article Snippet: Female Brown-Norway rats and C57BL/6 mice were obtained from Charles River (France) and female Harlan Hsd:Npa nu/nu (nude) athymic mice were obtained from the Novartis breeding stock (Basel, Switzerland).

Techniques: Injection